NATALIZUMAB (TYSABRI)

Course overview

Natalizumab is U.S. FDA-approved as monotherapy for relapsing multiple sclerosis (MS) in patients unresponsive to/intolerant of other MS therapies, and for moderate/severe Crohn disease (CD) in patients unresponsive to/intolerant of conventional therapy and tumor necrosis factor-alpha (TNF-α) inhibitors. It requires close monitoring because of the potential for liver toxicity and progressive multifocal leukoencephalopathy (PML). This continuing education module is designed to give the reader/learner an increased understanding of natalizumab. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.